Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)
NCT ID: NCT01082393
Last Updated: 2022-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
14 participants
INTERVENTIONAL
2010-02-16
2015-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vitiligo Treated With TL01 Combined With Tacrolimus Ointment Versus Placebo
NCT00807690
Effect of Early Systemic Stabilization Therapy on Recent Onset Vitiligo
NCT05037981
Effectivness of Topical Tacrolimus Monotherapy in Patients With Vitiligo
NCT03358082
Efficiency of Fractional-Laser Resurfacing Followed by Topical Tacrolimus 0.03% Cream vs Tacrolimus Alone in Vitiligo
NCT03535051
Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo
NCT01333410
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
topical tacrolimus
topical tacrolimus treatment
4 applications (day 1,day 3, day 6 and day10)
topical pimecrolimus
topical pimecrolimus treatment
4 applications (day 1, day 3, day 6 and day 10)
local steroids
local mometasone furoate treatment
4 applications (day 1, day 3, day 6 and day 10)
cold cream
cold cream
4 applications (day 1, day 3, day 6 and day 10)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
topical tacrolimus treatment
4 applications (day 1,day 3, day 6 and day10)
topical pimecrolimus treatment
4 applications (day 1, day 3, day 6 and day 10)
local mometasone furoate treatment
4 applications (day 1, day 3, day 6 and day 10)
cold cream
4 applications (day 1, day 3, day 6 and day 10)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-70 years,
* Extensive vitiligo (\> 50% body surface area),
* Patients asking for depigmenting therapy,
* Not pregnant.
Exclusion Criteria
* Non extensive vitiligo (\< 50% boy surface area),
* Patients not asking for depigmenting therapies,
* Pregnant.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Ghent
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nanny Van Geel, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Ghent
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Ghent
Ghent, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
website University Hospital Ghent
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009/599
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.